Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors

Brain and Nerve

Volumn 61, Issue 7, 2009, Pages 805-814

  Hashimoto, Naoya ^a   Tsuboi, Akihiro ^b   Chiba, Yasuyoshi ^a   Izumoto, Shuichi ^c   Oka, Yoshihiro ^b   Yoshimine, Toshiki ^a   Sugiyama, Haruo ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Glioblastoma; Malignant brain tumor; Vaccine; WT1 peptide

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; PEPTIDE VACCINE; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE; WT1 PROTEIN;

BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; MINIMAL RESIDUAL DISEASE; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; REVIEW; SOLID TUMOR; VACCINATION;

ANTIBODIES, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT; WT1 PROTEINS;

EID: 67849132176     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Committee of Brain Tumor Registry of Japan: Report of Brain Tumor Registry of Japan (1969-1996). Neurol Med Chir (Tokyo) 43 Suppl: 1-111, 2003
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2006 (Pubitemid 40349501)
3. Oka Y, Tsuboi A, Taguchi T, Osaki T, Sugiyama H, et al: Induction of WT1 (Wilm's tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101: 13885-13890, 2004 (Pubitemid 39298502)
4. Izumoto S, Tsuboi A, Oka Y, Hashimoto N, Yoshimine T, et al: Phase II clinical trial of WT1 (Wilms tumor gene) peptide vaccination for patients with recurrent glioblastoma. J Neurosurg 108: 963-971, 2008 (Pubitemid 351656845)
5. Barrett A J, Rezvani K: Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias. Clin Exp Immunol 148: 189-198, 2007 (Pubitemid 46587600)
6. Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20: 211-220, 2008
7. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, et al: Cancer immunotherapy targeting Wilm's tumor gene WT1 product. J Immunol 164: 1873-1880, 2000
8. Makita M, Hiraki A, Azuma T, Tsuboi A, Oka Y, et al: Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 8: 2626-2631, 2002 (Pubitemid 34856350)
9. Doubrovina ES, Doubrovin MM, Lee S, Shieh JH, Heller G, et al: In vitro stimulation with WT1 peptide- loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res 10: 7207-7219, 2004
10. Gao L, Bellantuono I, Elsässer A, Marley SB, Gordon M Y, et al: Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-2203, 2000 (Pubitemid 30167714)
11. Ohminami H, Yasukawa M, Fujita S: HLA class I- restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95: 286-293, 2000 (Pubitemid 30017254)
12. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, et al: Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilm's tumor gene (WT1product. Immunogenetics 51: 99-107, 2000
13. 187 as an HLA-A*0206-restricted, WT1-specific CTL epitope. Microbiol Immunol 52: 551-558, 2008
14. Oka Y, Tsuboi A, Elisseeva OA, Kawase I, Sugiyama H, et al: WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Scientific World Journal 7: 649-665, 2007 (Pubitemid 46849127)
15. Elisseeva O A, Oka Y, Tsuboi A, Ogata K, Wu F, et al: Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99: 3272-3279, 2002 (Pubitemid 34525307)
16. Rezvani K, Grube M, Brenchley JM, Sconochia G, Fujiwara H, et al: Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102: 2892-2900, 2003 (Pubitemid 37248862)
17. Oka Y, Tsuboi A, Murakami M, Kawase I, Sugiyama H, et al: Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78: 56-61, 2003 (Pubitemid 36899903)
18. Mailänder V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, et al: Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18: 165-166, 2004 (Pubitemid 38159453)
19. Rezvani K, Yong ASM, Mielke S, Savani BN, Musse L, et al: Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111: 236-242, 2008
20. Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva O A, et al: Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 86: 414-417, 2007
21. Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, et al: WT1 (Wilm's Tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-530, 2007 (Pubitemid 46799719)
22. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, et al: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 36: 231-236, 2006 (Pubitemid 43997323)
23. Oji, Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, et al: Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 95: 822-827, 2004 (Pubitemid 39545589)
24. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, et al: Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11: 5900-5911, 2005 (Pubitemid 41170319)
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000 (Pubitemid 30099779)
26. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17: 2572-2578, 1999
27. Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, et al: Identification and characterization of a WT1 (Wilms tumor gene) orotein-derived HLA-DRB1 * 0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother 30: 282-293, 2007 (Pubitemid 46586644)
28. Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, et al: Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365: 657-662, 2005 (Pubitemid 40260886)
29. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, et al: Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer sci 98: 605-611, 2007